alexa Prospects for Minocycline Neuroprotection
Pharmaceutical Sciences

Pharmaceutical Sciences

Pharmaceutical Regulatory Affairs: Open Access

Author(s): Plane JM

Abstract Share this page

The lack of robust treatment options available for neurodegenerative diseases, stroke, and central nervous system (CNS) trauma, all of which often involve both inflammation and apoptotic cell death, has led to an explosion of studies to reexamine the potential of established drugs for treatment of these conditions. Minocycline is a second-generation tetracycline derivative with a proven, safe clinical track record as an antibiotic and anti-inflammatory drug for treating acne and arthritis. Minocycline effectively crosses the blood-brain barrier and has demonstrated neuroprotective qualities in experimental models of CNS trauma, stroke, spinal cord injury, and neurodegenerative diseases including amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, and multiple sclerosis. Thus, it is not surprising that several off-label minocycline clinical trials are under way for a variety of CNS diseases. The emerging success of some of these trials raises optimism that minocycline treatment may soon be translated into clinical practice for CNS diseases, whereas others (eg, in amyotrophic lateral sclerosis) have raised red flags. A thorough understanding of minocycline's modes of action and the targeted cellular mechanisms is warranted, as are guidelines on safe and effective doses, routes of administration, and establishment of a therapeutic window. Although several lines of evidence point to a convergent action of minocycline in suppression of both apoptosis and CNS inflammation by preventing neural cell death and by inhibiting microglial activation, the exact molecular targets of minocycline have yet to be identified and characterized. This review provides an overview of the established mechanisms of action by which minocycline exerts its neuroprotective effects, summarizes results of animal studies in experimental models of neurological diseases, and discusses results of clinical trials.

This article was published in Arch Neurol and referenced in Pharmaceutical Regulatory Affairs: Open Access

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

  • European Biopharma Congress
    November 16-17, 2017 Vienna, Austria

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

1-702-714-7001Extn: 9037

Business & Management Journals


1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

1-702-714-7001 Extn: 9042

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version